NATPARA ®(PARATHYROID HORMONE)

Clinical pharmacology

Initial U.S. Approval: 2015

Mechanism of Action: NATPARA is a parathyroid hormone. Parathyroid hormone raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption (i.e., by converting 25 OH vitamin D to 1,25 OH2 vitamin D) and by increasing bone turnover which releases calcium into the circulation.

Indications and usage

INDICATIONS AND USAGE:
NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Limitations of Use:
Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. [see Warnings and Precautions (5.1)]
NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations.
NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

Dosage and administration

Drug UPDATES: NATPARA ®(PARATHYROID HORMONE)- parathyroid hormone injection
[Drug information / PDF] Click link for the latest monograph
Dosing: Click (+) next to Dosage and Administration section (drug info link)

How supplied

HOW SUPPLIED: NATPARA is supplied as a multiple dose, dual-chamber glass cartridge containing a sterile powder and diluent in 4 dosage strengths. [25, 50, 75, 100 mcg]

Reference

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.